Cargando…
Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials
BACKGROUND: A model was built that characterized effects of individual factors on five-year prostate cancer (PCa) risk in the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCO) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). This model was validated in a third San Anto...
Autores principales: | Gelfond, Jonathan A., Hernandez, Brian, Goros, Martin, Ibrahim, Joseph G., Chen, Ming-Hui, Sun, Wei, Leach, Robin J., Kattan, Michael W., Thompson, Ian M., Ankerst, Donna Pauler, Liss, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966358/ https://www.ncbi.nlm.nih.gov/pubmed/35351104 http://dx.doi.org/10.1186/s12894-022-00986-w |
Ejemplares similares
-
The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial
por: Hernandez, Javier, et al.
Publicado: (2018) -
A case control study of sarcosine as an early prostate cancer detection biomarker
por: Ankerst, Donna P., et al.
Publicado: (2015) -
Seropositivity for Helicobacter pylori and hepatobiliary cancers in the PLCO study
por: Makkar, Rishi, et al.
Publicado: (2020) -
Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools
por: Tolksdorf, Johanna, et al.
Publicado: (2019) -
Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study
por: Shebl, F M, et al.
Publicado: (2012)